{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:39:28Z","timestamp":1762324768902},"reference-count":77,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mantle cell lymphoma is a rare, aggressive, and largely incurable form of non-Hodgkin lymphoma. There are a number of well-characterized prognostic features but nothing that can help guide therapy. Treatment with chemotherapy is generally effective in the short term, but relapse is inevitable and subsequent treatment is challenging. The use of Bruton tyrosine kinase inhibitors, however, has transformed practice. These agents are highly active in relapsed disease and are very well-tolerated drugs. Chemotherapy-free combinations using Bruton tyrosine kinase inhibitors look very exciting and will likely evolve to be part of frontline care in the future.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000462","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T01:15:40Z","timestamp":1595466940000},"page":"348-356","source":"Crossref","is-referenced-by-count":3,"title":["Advances in Classification and Treatment of Non-Hodgkin Lymphoma"],"prefix":"10.1097","volume":"26","author":[{"given":"Simon","family":"Rule","sequence":"first","affiliation":[{"name":"Plymouth University Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Johns","sequence":"additional","affiliation":[{"name":"University Hospital Plymouth, Plymouth, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20230924","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/00000478-199207000-00001","article-title":"Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data","volume":"16","year":"1992","journal-title":"Am J Surg Pathol"},{"key":"bib2-20230924","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","article-title":"Molecular pathogenesis of mantle cell lymphoma","volume":"122","year":"2012","journal-title":"J Clin Invest"},{"key":"bib3-20230924","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics","volume":"7","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"bib4-20230924","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","year":"2016","journal-title":"Blood"},{"key":"bib5-20230924","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2009.010264","article-title":"SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype","volume":"94","year":"2009","journal-title":"Haematologica"},{"key":"bib6-20230924","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib7-20230924","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First line treatment of patients with indolent non-Hodgkin lymphoma or mantle cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5 year follow up study","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib8-20230924","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","article-title":"Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL network","volume":"131","year":"2018","journal-title":"Blood"},{"key":"bib9-20230924","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":"Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma","volume":"70","year":"2010","journal-title":"Cancer Res"},{"key":"bib10-20230924","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3324\/haematol.2010.036277","article-title":"Indolent mantle cell leukemia: clinicopathologic variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis","volume":"96","year":"2011","journal-title":"Haematologica"},{"key":"bib11-20230924","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2012-08-452284","article-title":"CCND2 rearrangements are the most frequent genetic events in cyclin D1(\u2212) mantle cell lymphoma","volume":"121","year":"2013","journal-title":"Blood"},{"key":"bib12-20230924","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","year":"2008","journal-title":"Blood"},{"key":"bib13-20230924","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large B-cell lymphomas","volume":"359","year":"2008","journal-title":"N Engl J Med"},{"key":"bib14-20230924","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European mantle cell lymphoma network","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib15-20230924","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/bloodadvances.2019001396","article-title":"Genomic profiles and clinical outcomes of de novo blastoid\/pleomorphic MCL are distinct from those of transformed MCL","volume":"4","year":"2020","journal-title":"Blood Adv"},{"key":"bib16-20230924","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib17-20230924","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3324\/haematol.2018.214056","article-title":"KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study","volume":"105","year":"2020","journal-title":"Haematologica"},{"key":"bib18-20230924","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood-2018-03-838136","article-title":"A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib19-20230924","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2016.70.7901","article-title":"New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib20-20230924","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/bjh.15518","article-title":"The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy","volume":"183","year":"2018","journal-title":"Br J Haematol"},{"key":"bib21-20230924","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood-2016-03-635219","article-title":"Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma","volume":"127","year":"2016","journal-title":"Blood"},{"key":"bib22-20230924","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","year":"2019","journal-title":"Nat Med"},{"key":"bib23-20230924","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","year":"2009","journal-title":"J Clin Oncol"},{"key":"bib24-20230924","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1093\/annonc\/mdx333","article-title":"Observation as the initial management strategy in patients with mantle cell lymphoma","volume":"28","year":"2017","journal-title":"Ann Oncol"},{"journal-title":"Hematol Oncol","article-title":"Radiotherapy in mantle cell lymphoma: a literature review [published online December 24, 2019]","year":"2019","key":"bib25-20230924"},{"key":"bib26-20230924","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1093\/annonc\/mdx334","article-title":"Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"28","year":"2017","journal-title":"Ann Oncol"},{"key":"bib27-20230924","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European","volume":"105","year":"2005","journal-title":"Blood"},{"key":"bib28-20230924","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL younger): a randomised, open-label, phase 3 trial of the European mantle cell lymphoma network","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"bib29-20230924","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with rituximab-HyperCVAD alternating with rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","year":"2010","journal-title":"Br J Haematol"},{"key":"bib30-20230924","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"bib31-20230924","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/bjh.15721","article-title":"Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations","volume":"184","year":"2019","journal-title":"Br J Haematol"},{"key":"bib32-20230924","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma","volume":"18","year":"2000","journal-title":"J Clin Oncol"},{"key":"bib33-20230924","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3324\/haematol.2015.128710","article-title":"The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial","volume":"101","year":"2016","journal-title":"Haematologica"},{"key":"bib34-20230924","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","year":"2013","journal-title":"Lancet"},{"key":"bib35-20230924","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","year":"2012","journal-title":"N Engl J Med"},{"key":"bib36-20230924","first-page":"1","article-title":"Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma","volume":"11","year":"2018","journal-title":"Lancet Oncol"},{"key":"bib37-20230924","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1182\/blood.V128.22.1802.1802","article-title":"Maintenance therapy for patients with mantle cell lymphoma (MCL)\u2014a systematic review and meta-analysis of randomized controlled trials (RCTs)","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib38-20230924","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(16)30185-5","article-title":"Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi","volume":"4","year":"2017","journal-title":"Lancet Haematol"},{"key":"bib39-20230924","first-page":"1","article-title":"Five-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib40-20230924","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","year":"2019","journal-title":"Blood Cancer J"},{"key":"bib41-20230924","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.bbmt.2010.04.006","article-title":"Outcome following reduced-intensity allogeneic stem cell transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation","volume":"16","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"bib42-20230924","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","year":"2006","journal-title":"J Clin Oncol"},{"key":"bib43-20230924","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma","volume":"22","year":"2011","journal-title":"Ann Oncol"},{"key":"bib44-20230924","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","year":"2009","journal-title":"J Clin Oncol"},{"key":"bib45-20230924","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib46-20230924","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","year":"2013","journal-title":"J Clin Oncol"},{"key":"bib47-20230924","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"key":"bib48-20230924","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"bib49-20230924","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","article-title":"Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis","volume":"104","year":"2019","journal-title":"Haematologica"},{"key":"bib50-20230924","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41409-018-0207-4","article-title":"Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT chronic malignancies and lymphoma working parties","volume":"54","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"bib51-20230924","first-page":"659","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","year":"2017","journal-title":"Lancet"},{"journal-title":"Clin Cancer Res","article-title":"Treatment of patients with relapsed or refractory mantle cell lymphoma with zanubrutinib, a selective inhibitor of Bruton's tyrosine kinase [published online May 27, 2020]","year":"2020","key":"bib52-20230924"},{"key":"bib53-20230924","first-page":"245","article-title":"Updated safety and efficacy data in the phase I trial of patients with mantle cell lymphoma (MCL) treated with the Bruton tyrosine kinase (BTK) inhibitor Zanubrutinib (BGB-3111)","volume":"37","year":"2019","journal-title":"International Conference on Malignant Lymphoma (ICML)"},{"key":"bib54-20230924","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/s41375-019-0658-7","article-title":"Long term follow up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS\/ONO-4049)","volume":"34","year":"2020","journal-title":"Leukaemia"},{"key":"bib55-20230924","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"key":"bib56-20230924","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood-2014-08-597914","article-title":"A phase 1\/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed\/refractory non-Hodgkin lymphoma","volume":"125","year":"2015","journal-title":"Blood"},{"key":"bib57-20230924","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"Results of a phase I study of idelalisib, a PI3K\u03b4 inhibitor, in patients with relapsed or refractory mantle cell lymphoma (MCL)","volume":"123","year":"2014","journal-title":"Blood"},{"key":"bib58-20230924","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1182\/blood-2014-12-619163","article-title":"Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy","volume":"125","year":"2015","journal-title":"Blood"},{"key":"bib59-20230924","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(18)30196-0","article-title":"Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1\u20131b study","volume":"6","year":"2019","journal-title":"Lancet Haematol"},{"key":"bib60-20230924","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","year":"2012","journal-title":"Lancet Oncol"},{"key":"bib61-20230924","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/S2352-3026(18)30018-8","article-title":"Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial","volume":"5","year":"2018","journal-title":"Lancet Haematol"},{"key":"bib62-20230924","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","article-title":"Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma","volume":"119","year":"2012","journal-title":"Blood"},{"key":"bib63-20230924","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood-2018-11-886457","article-title":"A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma","volume":"133","year":"2019","journal-title":"Blood"},{"key":"bib64-20230924","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib65-20230924","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","article-title":"Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy","volume":"104","year":"2019","journal-title":"Haematologica"},{"key":"bib66-20230924","first-page":"757","article-title":"Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways","volume":"168","year":"2015","journal-title":"Br J Haematol"},{"key":"bib67-20230924","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"key":"bib68-20230924","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib69-20230924","first-page":"1","article-title":"Overcoming ibrutinib resistance in chronic lymphocytic leukemia","volume":"11","year":"2019","journal-title":"Cancers (Basel)"},{"key":"bib70-20230924","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"bib71-20230924","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB\u2013targeted treatment strategies for mantle cell lymphoma","volume":"20","year":"2014","journal-title":"Nat Med"},{"key":"bib72-20230924","first-page":"849","article-title":"Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells","volume":"116","year":"2014","journal-title":"Br J Haematol"},{"key":"bib73-20230924","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","year":"2016","journal-title":"Blood [Internet]"},{"key":"bib74-20230924","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","year":"2015","journal-title":"Ann Oncol"},{"key":"bib75-20230924","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13045-017-0537-5","article-title":"Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed\/progressed after or were refractory\/intolerant to ibrutinib (MCL-004)","volume":"10","year":"2017","journal-title":"J Hematol Oncol"},{"key":"bib76-20230924","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.16416","article-title":"Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy","volume":"189","year":"2020","journal-title":"Br J Haematol"},{"key":"bib77-20230924","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","year":"2020","journal-title":"N Engl J Med"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T15:38:55Z","timestamp":1723304335000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000462"}},"subtitle":["Mantle Cell"],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000462","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"type":"electronic","value":"1540-336X"},{"type":"print","value":"1528-9117"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}